XSHE
002382
Market cap990mUSD
Oct 09, Last price
6.79CNY
1D
3.19%
1Q
29.58%
Jan 2017
-44.21%
IPO
-28.27%
Name
Blue Sail Medical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Blue Sail Medical Co.,Ltd. is a global enterprise based in Zibo, China, specializing in the production and distribution of a wide array of protective gloves. Its offerings include disposable medical, latex, nitrile, PVC, TPE, and household gloves, which are utilized across various sectors such as medical examination and protection, food processing, and the electronics industry. Beyond its glove business, the company actively engages in the research, development, manufacturing, and sales of cardiac stents and associated equipment for interventional cardiac surgery. Established in 2002, the company was formerly named Shandong Blue Sail Plastic & Rubber Co., Ltd. before adopting its current identity, Blue Sail Medical Co.,Ltd., in July 2014.
Key people
Shuqiao Zhong
President, Director · since 2022
Yuntao Cui
Chief Financial Officer, Vice President · since 2022
Yongchen Zhang
Vice President, General Manager - Emergency Rescue Division · since 2024
Mucun Zhang
Vice President, Deputy General Manager - Protection Division · since 2022
Suhua Yu
General Manager - Cardiovascular Division, Director · since 2022
Ziyi Wang
Secretary of the Board · since 2025
Zhenping Li
Director · since 2010
Wenjing Liu
Chairman of the Board · since 2022
Min Zhao
Staff Elected Director · since 2025
Independent Director · since 2024
Guitao Qiao
Independent Director · since 2023
Yongqing Zhao
Independent Director · since 2024
Headquarters & legal address
山东省淄博市齐鲁化学工业区清田路21号
淄博市, SD 100000
CN
淄博市, SD 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||